Pascha, M. N. http://orcid.org/0000-0003-4382-1979
Ballegeer, M.
Roelofs, M. C.
Meuris, L. http://orcid.org/0000-0001-8940-3022
Albulescu, I. C.
van Kuppeveld, F. J. M. http://orcid.org/0000-0001-5800-749X
Hurdiss, D. L. http://orcid.org/0000-0003-3834-5808
Bosch, B. J. http://orcid.org/0000-0002-3864-232X
Zeev-Ben-Mordehai, T.
Saelens, X. http://orcid.org/0000-0002-3861-6965
de Haan, C. A. M. http://orcid.org/0000-0002-4459-9874
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (874650, 874650)
Health~Holland, Top Sector Life Sciences & Health, The Netherlands https://www.health-holland.com/
Health~Holland, Top Sector Life Sciences & Health, The Netherlands https://www.health-holland.com/
Article History
Received: 8 November 2023
Accepted: 20 May 2024
First Online: 31 May 2024
Competing interests
: The authors declare the following competing interests: X.S. is Associate Editor of NPJ Vaccines and C.A.M.H. was a member of the ADD-NA (Adding Neuraminidase) Delphi panel supported by Seqirus. All other authors declare no competing interests.